The Wegovy Group of Medicines: What They Are and Whether One Might Be Right for You

What the GLP-1 group actually does in the body

GLP-1 stands for glucagon-like peptide-1, a hormone naturally released from the gut after eating. Medicines in this group (including semaglutide) mimic that hormone's effects: they slow gastric emptying, increase the feeling of fullness and reduce appetite signals reaching the brain. Wegovy delivers semaglutide by once-weekly subcutaneous injection, while the newer Wegovy tablet delivers it orally each morning. Neither is a stimulant or a fat-blocker; the mechanism is hormonal.

It is worth being clear about what sits inside this group and what does not. Ozempic is also semaglutide, but it is licensed for type 2 diabetes management, not for weight loss. Rybelsus is oral semaglutide at lower doses, again for diabetes. When a prescriber or a regulator refers to the "semaglutide group" in a weight-loss context, they mean Wegovy specifically. You can read more about how the broader semaglutide group of drugs is structured and where the licensing boundaries fall. Tirzepatide (Mounjaro) belongs to a related but distinct class (it activates both GLP-1 and GIP receptors) so the two groups overlap in purpose but not in mechanism.

For people weighing up which medicine to discuss with a prescriber, the weight-loss treatment overview sets out how the licensed options compare on the evidence available.

Who the licensed criteria point to — and where the decision gets more nuanced

The UK licence for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. A BMI that clears the threshold is necessary, but it is not sufficient on its own.

Prescribers look at the full clinical picture: which other medicines you take, any history of pancreatitis or gallbladder disease, thyroid history, and whether you are pregnant, breastfeeding or trying to conceive. Wegovy is not recommended in those situations. It is also not licensed for people under 18. The Wegovy overview page covers the eligibility landscape in more detail, including how NICE's recommendation under TA875 shapes NHS access versus private prescribing routes.

What the criteria do not resolve is whether Wegovy is the right choice within the licensed group, whether the injection format suits you better than the tablet, for example, or whether you'd prefer to discuss tirzepatide instead. That is the kind of conversation a prescriber is there for.

Injection, tablet and dose: what the group looks like in practice

The injectable Wegovy pen starts at 0.25mg weekly and titrates upward over several months to a maintenance dose of 2.4mg, and now up to 7.2mg following MHRA approval of the single-dose 7.2mg pen in April 2026. The injection goes into the abdomen, thigh or upper arm; most people keep their pens in the fridge door and rotate injection sites week by week.

The Wegovy tablet follows a different schedule: once daily, taken on an empty stomach first thing in the morning with a small amount of plain water, at least 30 minutes before any food or drink. No refrigeration is needed, which some people find genuinely convenient for travel or simply for consistency. Hair changes are an occasional question in the semaglutide group, our pages on hair changes during Wegovy treatment and whether hair grows back after semaglutide cover what the evidence shows.

Side effects across both formats are predominantly gastrointestinal: nausea, loose stools, constipation and indigestion are the most reported, typically peaking after a dose increase and settling within days to a couple of weeks. Severe, persistent stomach pain radiating to the back needs prompt medical attention, it can signal pancreatitis, which the MHRA flagged as an infrequent but serious risk in its January 2026 Drug Safety Update. Patients can report suspected side effects directly at the MHRA Yellow Card service.

What the decision actually hinges on

For most people researching the Wegovy group, the real question is not "what is semaglutide" but "is this worth starting, and will I be supported if I do". Both are fair. The clinical evidence is substantial: the STEP 1 trial (68 weeks, 2.4mg injectable semaglutide) showed an average body-weight reduction of around 15%, and the 7.2mg data suggest figures closer to 20%. The oral Wegovy trial showed around 13.6% average weight loss over 64 weeks regardless of adherence, or roughly 17% among participants who stayed fully on the protocol.

None of those figures are promises; trial populations and real-world conditions differ. The other side of the decision is practical support. If you are curious about peer experience, the Wegovy support community resources in the UK page gives a realistic picture of what community groups offer. Travelling on Wegovy raises its own questions; taking Wegovy through airport security is a common concern worth reading about before a trip.

Wegovy is available only on a private prescription through a regulated UK pharmacy, or through NHS specialist services for those who meet NICE TA875 criteria. For a straightforward look at how private access works and what the cost landscape looks like, the how to get Wegovy in the UK page is the clearest starting point. When you are ready to discuss whether it is right for your situation, the next step is a clinical conversation. Speak to our prescribers through a free consultation, a real clinician reviews your answers the same day, not a piece of software.